Matthew Dy

Overview

CEO of Cell and Gene Therapy Catapult (UK), challenging the 'process is the product' axiom and building rare disease manufacturing platforms through aggregated scale and prior knowledge reuse. Matthew Dy leads the Cell and Gene Therapy Catapult, a UK independent not-for-profit with a mission to deliver cell and gene therapies to patients worldwide, operating across four areas: early-stage technology translation to commercialization, process and clinical development, manufacturing development via IT and automation, and a hospital network for standards and implementation. Dy challenges the industry axiom 'the process is the product,' arguing that its historical meaning — manufacturers had so little process understanding and so little ability to characterize the end product that they never changed anything — represents a 20-year failure that must be urgently corrected. (Segment 2-3 (05:00-15:00))